Literature DB >> 26057816

Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.

Vivian Cody1, Jim Pace1, Ojas A Namjoshi2, Aleem Gangjee2.   

Abstract

To further define the interactions that enhance the selectivity of binding and to directly compare the binding of the most potent analogue {N(6)-methyl-N(6)-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine; compound 26} in the series of bicyclic pyrido[2,3-d]pyrimidine analogues of piritrexim (PTX) with native human (h), Pneumocystis carinii (pc) and Pneumocystis jirovecii (pj) dihydrofolate reductase (DHFR) enzymes, the crystal structures of hDHFR complexed with N(6)-methyl-N(6)-(4-isopropylphenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine (compound 22), of hDHFR complexed with compound 26 and of pcDHFR complexed with N(6)-methyl-N(6)-1-naphthylpyrido[2,3-d]pyrimidine-2,4,6-triamine (compound 24) are reported as ternary complexes with NADPH. This series of bicyclic pyrido[2,3-d]pyrimidines were designed in which there was a transposition of the 5-methyl group of PTX to the N9 position of the pyrido[2,3-d]pyrimidine. It was hypothesized that the N9-methyl group would preferentially interact with Ile123 of pcDHFR (and Ile123 of pjDHFR), but not with the shorter Val115 in hDHFR. Structure-activity data for this series of antifolates revealed that a trifluoro derivative (26) was the most selective against pjDHFR compared with mammalian DHFR (h/pj = 35.7). Structural data for the hDHFR-26 complex revealed that 26 binds in a different conformation from that observed in the pcDHFR-26 complex. In the hDHFR-26 complex the trifluorophenyl ring of 26 occupies a position near the cofactor-binding site, with close intermolecular contacts with Asp21, Ser59 and Ile60, whereas this ring in the pcDHFR-26 complex is positioned away from the cofactor site and near Ile65, with weaker contacts with Ile65, Phe69 and Ile123. Comparison of the intermolecular contacts between the N9-methyl group with Val115/Ile123 validates the hypothesis that the N9-methyl substituent preferentially interacts with Ile123 compared with Val115 of hDHFR, as the weaker contact with Val115 in the hDHFR structure is consistent with its weaker binding affinity compared with pcDHFR. The results for the structures of hDHFR-22 and pcDHFR-24 show that their inhibitor-binding orientation is similar to that observed in pcDHFR-26 and the pcDHFR variant (F69N) reported previously. The naphthyl moiety of 24 makes several intermolecular contacts with the active-site residues in pcDHFR that help to stabilize the binding, resulting in a more potent inhibitor.

Entities:  

Keywords:  Pneumocystis carinii; antifolate inhibitors; conformational analysis; dihydrofolate reductase; pathogens

Mesh:

Substances:

Year:  2015        PMID: 26057816      PMCID: PMC4461351          DOI: 10.1107/S2053230X15008468

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  12 in total

1.  Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines.

Authors:  Timothy M McPhillips; Scott E McPhillips; Hsiu-Ju Chiu; Aina E Cohen; Ashley M Deacon; Paul J Ellis; Elspeth Garman; Ana Gonzalez; Nicholas K Sauter; R Paul Phizackerley; S Michael Soltis; Peter Kuhn
Journal:  J Synchrotron Radiat       Date:  2002-11-01       Impact factor: 2.616

2.  Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Sudhir Raghavan; Sherry F Queener; Roy L Kisliuk; Vivian Cody
Journal:  J Med Chem       Date:  2013-05-21       Impact factor: 7.446

3.  An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot.

Authors:  Aina E Cohen; Paul J Ellis; Mitchell D Miller; Ashley M Deacon; R Paul Phizackerley
Journal:  J Appl Crystallogr       Date:  2002-12       Impact factor: 3.304

4.  Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.

Authors:  J A Kovacs; C J Allegra; J C Swan; J C Drake; J E Parrillo; B A Chabner; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH.

Authors:  Vivian Cody; Joe R Luft; Walt Pangborn
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-01-19

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.

Authors:  E M Grivsky; S Lee; C W Sigel; D S Duch; C A Nichol
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

8.  Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.

Authors:  Aleem Gangjee; Wei Li; Lu Lin; Yibin Zeng; Michael Ihnat; Linda A Warnke; Dixy W Green; Vivian Cody; Jim Pace; Sherry F Queener
Journal:  Bioorg Med Chem       Date:  2009-08-22       Impact factor: 3.641

9.  REFMAC5 for the refinement of macromolecular crystal structures.

Authors:  Garib N Murshudov; Pavol Skubák; Andrey A Lebedev; Navraj S Pannu; Roberto A Steiner; Robert A Nicholls; Martyn D Winn; Fei Long; Alexei A Vagin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

10.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  4 in total

1.  Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.

Authors:  Khushbu Shah; Sherry Queener; Vivian Cody; Jim Pace; Aleem Gangjee
Journal:  Bioorg Med Chem Lett       Date:  2019-06-04       Impact factor: 2.823

2.  Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.

Authors:  Khushbu Shah; Xin Lin; Sherry F Queener; Vivian Cody; Jim Pace; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2018-04-17       Impact factor: 3.641

3.  Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.

Authors:  Michele Tonelli; Lieve Naesens; Sabrina Gazzarrini; Matteo Santucci; Elena Cichero; Bruno Tasso; Anna Moroni; Maria Paola Costi; Roberta Loddo
Journal:  Eur J Med Chem       Date:  2017-04-27       Impact factor: 6.514

4.  Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).

Authors:  Valeria Francesconi; Luca Giovannini; Matteo Santucci; Elena Cichero; Maria Paola Costi; Lieve Naesens; Fabrizio Giordanetto; Michele Tonelli
Journal:  Eur J Med Chem       Date:  2018-06-02       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.